Imperial College London
Alternate

Dr Céire Costelloe

Faculty of Medicine, School of Public Health

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 7594 0799ceire.costelloe

 
 
//

Location

 

326Reynolds BuildingCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Barnes:2016:10.3310/hta20290,
author = {Barnes, TR and Leeson, VC and Paton, C and Costelloe, C and Simon, J and Kiss, N and Osborn, D and Killaspy, H and Craig, TK and Lewis, S and Keown, P and Ismail, S and Crawford, M and Baldwin, D and Lewis, G and Geddes, J and Kumar, M and Pathak, R and Taylor, S},
doi = {10.3310/hta20290},
journal = {Health Technology Assessment},
title = {Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial},
url = {http://dx.doi.org/10.3310/hta20290},
volume = {20},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes associated with schizophrenia. There are currently no approved pharmacological treatments. While the available evidence suggests that a combination of antipsychotic and antidepressant medication may be effective in treating negative symptoms, it is too limited to allow any firm conclusions. OBJECTIVE: To establish the clinical effectiveness and cost-effectiveness of augmentation of antipsychotic medication with the antidepressant citalopram for the management of negative symptoms in schizophrenia. DESIGN: A multicentre, double-blind, individually randomised, placebo-controlled trial with 12-month follow-up. SETTING: Adult psychiatric services, treating people with schizophrenia. PARTICIPANTS: Inpatients or outpatients with schizophrenia, on continuing, stable antipsychotic medication, with persistent negative symptoms at a criterion level of severity. INTERVENTIONS: Eligible participants were randomised 1 : 1 to treatment with either placebo (one capsule) or 20 mg of citalopram per day for 48 weeks, with the clinical option at 4 weeks to increase the daily dosage to 40 mg of citalopram or two placebo capsules for the remainder of the study. MAIN OUTCOME MEASURES: The primary outcomes were quality of life measured at 12 and 48 weeks assessed using the Heinrich's Quality of Life Scale, and negative symptoms at 12 weeks measured on the negative symptom subscale of the Positive and Negative Syndrome Scale. RESULTS: No therapeutic benefit in terms of improvement in quality of life or negative symptoms was detected for citalopram over 12 weeks or at 48 weeks, but secondary analysis suggested modest improvement in the negative symptom domain, avolition/amotivation, at 12 weeks (mean difference -1.3, 95% confidence inter
AU  - Barnes,TR
AU  - Leeson,VC
AU  - Paton,C
AU  - Costelloe,C
AU  - Simon,J
AU  - Kiss,N
AU  - Osborn,D
AU  - Killaspy,H
AU  - Craig,TK
AU  - Lewis,S
AU  - Keown,P
AU  - Ismail,S
AU  - Crawford,M
AU  - Baldwin,D
AU  - Lewis,G
AU  - Geddes,J
AU  - Kumar,M
AU  - Pathak,R
AU  - Taylor,S
DO  - 10.3310/hta20290
PY  - 2016///
SN  - 1366-5278
TI  - Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial
T2  - Health Technology Assessment
UR  - http://dx.doi.org/10.3310/hta20290
UR  - http://hdl.handle.net/10044/1/32372
VL  - 20
ER  -
Download